Search

Your search keyword '"Bruce, Lars"' showing total 24 results

Search Constraints

Start Over You searched for: Author "Bruce, Lars" Remove constraint Author: "Bruce, Lars" Search Limiters Available in Library Collection Remove constraint Search Limiters: Available in Library Collection
24 results on '"Bruce, Lars"'

Search Results

1. A low molecular weight dextran sulphate, ILB®, for the treatment of amyotrophic lateral sclerosis (ALS): An open-label, single-arm, single-centre, phase II trial.

3. Cognitive and behavioral profile in a case of right anterior temporal lobe neurodegeneration.

4. The mechanism of action of a novel neuroprotective low molecular weight dextran sulphate: New platform therapy for neurodegenerative diseases like Amyotrophic Lateral Sclerosis

5. ILB®, a Low Molecular Weight Dextran Sulphate, Restores Glutamate Homeostasis, Amino Acid Metabolism and Neurocognitive Functions in a Rat Model of Severe Traumatic Brain Injury

7. ILB® Attenuates Clinical Symptoms and Serum Biomarkers of Oxidative/Nitrosative Stress and Mitochondrial Dysfunction in Patients with Amyotrophic Lateral Sclerosis

8. ILB ® , a Low Molecular Weight Dextran Sulphate, Restores Glutamate Homeostasis, Amino Acid Metabolism and Neurocognitive Functions in a Rat Model of Severe Traumatic Brain Injury.

9. A phase II open label clinical study of the safety, tolerability and efficacy of ILB® for Amyotrophic Lateral Sclerosis.

10. Brain volumetric deficits in MAPT mutation carriers: a multisite study

11. Low Molecular Weight Dextran Sulfate (ILB®) Administration Restores Brain Energy Metabolism Following Severe Traumatic Brain Injury in the Rat

12. Genetic variation across RNA metabolism and cell death gene networks is implicated in the semantic variant of primary progressive aphasia

13. Genetically elevated high-density lipoprotein cholesterol through the cholesteryl ester transfer protein gene does not associate with risk of Alzheimer's disease

14. Downregulation of exosomal miR-204-5p and miR-632 as a biomarker for FTD: A GENFI study

15. Poly(GP), neurofilament and grey matter deficits in C9orf72 expansion carriers

16. Poly(GP) proteins are a useful pharmacodynamic marker for C9ORF72-associated amyotrophic lateral sclerosis

17. Processing Electronic Medical Records : Ontology-Driven Information Extraction and Structuring in the Clinical Domain

18. Frontotemporal dementia and its subtypes: A genome-wide association study

19. Redesign of the Oz Compiler

20. FUS pathology defines the majority of tau-and TDP-43-negative frontotemporal lobar degeneration

22. ILB ® Attenuates Clinical Symptoms and Serum Biomarkers of Oxidative/Nitrosative Stress and Mitochondrial Dysfunction in Patients with Amyotrophic Lateral Sclerosis.

23. A low molecular weight dextran sulphate, ILB®, for the treatment of amyotrophic lateral sclerosis (ALS): An open-label, single-arm, single-centre, phase II trial.

24. Low Molecular Weight Dextran Sulfate (ILB ® ) Administration Restores Brain Energy Metabolism Following Severe Traumatic Brain Injury in the Rat.

Catalog

Books, media, physical & digital resources